Effects of dopaminergic agonists and antagonists on [3H]apomorphine binding to striatal membranes: sulpiride lack of interactions with positive cooperative [3H]apomorphine binding. 1980

N Fujita, and K Saito, and A Hirata, and K Iwatsubo, and Y Noguchi, and H Yoshida

Effects of dopaminergic agonists and antagonists on [3H]apomorphine binding to striatal membranes of rat brain was examined. Haloperidol and spiroperidol exhibited biphasic inhibition of [3H]apomorphine binding; one of which had the Hill coefficient of 0.9, whereas the other had that of 0.4. The former accounted for 65% of [3H]apomorphine binding while the latter consisted of 35% of the binding. Furthermore, the latter disappeared after kainic acid lesions. On the other hand, sulpiride and metoclopramide reduced [3H]apomorphine binding to 31% with the Hill coefficient of 0.9. The inhibition of [3H]apomorphine binding with the Hill coefficient of 0.4 which was shown by haloperidol and spiroperidol was not observed for sulpiride and metoclopramide. Previously, we demonstrated non- and positive-cooperative [3H]apomorphine binding to stiatal membranes. In the present study, it has been also shown that sulpiride inhibits non-cooperative [3H]apomorphine binding leaving that with allosteric properties unaffected. No inhibition of dopamine-sensitive adenylate cyclase was observed by 10(-4) M sulpiride while 90% inhibition was obtained with 10(-5) M haloperidol. From those results, it is suggested that non-cooperative [3H]spomorphine binding is not coupled with dopamine-sensitive adenylate cyclase.

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008297 Male Males
D011954 Receptors, Dopamine Cell-surface proteins that bind dopamine with high affinity and trigger intracellular changes influencing the behavior of cells. Dopamine Receptors,Dopamine Receptor,Receptor, Dopamine
D002462 Cell Membrane The lipid- and protein-containing, selectively permeable membrane that surrounds the cytoplasm in prokaryotic and eukaryotic cells. Plasma Membrane,Cytoplasmic Membrane,Cell Membranes,Cytoplasmic Membranes,Membrane, Cell,Membrane, Cytoplasmic,Membrane, Plasma,Membranes, Cell,Membranes, Cytoplasmic,Membranes, Plasma,Plasma Membranes
D003342 Corpus Striatum Striped GRAY MATTER and WHITE MATTER consisting of the NEOSTRIATUM and paleostriatum (GLOBUS PALLIDUS). It is located in front of and lateral to the THALAMUS in each cerebral hemisphere. The gray substance is made up of the CAUDATE NUCLEUS and the lentiform nucleus (the latter consisting of the GLOBUS PALLIDUS and PUTAMEN). The WHITE MATTER is the INTERNAL CAPSULE. Lenticular Nucleus,Lentiform Nucleus,Lentiform Nuclei,Nucleus Lentiformis,Lentiformis, Nucleus,Nuclei, Lentiform,Nucleus, Lenticular,Nucleus, Lentiform,Striatum, Corpus
D006220 Haloperidol A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279) Haldol
D000262 Adenylyl Cyclases Enzymes of the lyase class that catalyze the formation of CYCLIC AMP and pyrophosphate from ATP. Adenyl Cyclase,Adenylate Cyclase,3',5'-cyclic AMP Synthetase,Adenylyl Cyclase,3',5' cyclic AMP Synthetase,AMP Synthetase, 3',5'-cyclic,Cyclase, Adenyl,Cyclase, Adenylate,Cyclase, Adenylyl,Cyclases, Adenylyl,Synthetase, 3',5'-cyclic AMP
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001058 Apomorphine A derivative of morphine that is a dopamine D2 agonist. It is a powerful emetic and has been used for that effect in acute poisoning. It has also been used in the diagnosis and treatment of parkinsonism, but its adverse effects limit its use. Apokinon,Apomorphin-Teclapharm,Apomorphine Chloride,Apomorphine Hydrochloride,Apomorphine Hydrochloride Anhydrous,Apomorphine Hydrochloride, Anhydrous,Apomorphine Hydrochloride, Hemihydrate,Britaject,Apomorphin Teclapharm
D001667 Binding, Competitive The interaction of two or more substrates or ligands with the same binding site. The displacement of one by the other is used in quantitative and selective affinity measurements. Competitive Binding

Related Publications

N Fujita, and K Saito, and A Hirata, and K Iwatsubo, and Y Noguchi, and H Yoshida
January 1981, Neuroscience,
N Fujita, and K Saito, and A Hirata, and K Iwatsubo, and Y Noguchi, and H Yoshida
February 1987, Brain research,
N Fujita, and K Saito, and A Hirata, and K Iwatsubo, and Y Noguchi, and H Yoshida
August 1985, Biochemical pharmacology,
N Fujita, and K Saito, and A Hirata, and K Iwatsubo, and Y Noguchi, and H Yoshida
January 1981, European journal of pharmacology,
N Fujita, and K Saito, and A Hirata, and K Iwatsubo, and Y Noguchi, and H Yoshida
December 1981, Neuropharmacology,
N Fujita, and K Saito, and A Hirata, and K Iwatsubo, and Y Noguchi, and H Yoshida
June 1979, The Journal of pharmacy and pharmacology,
N Fujita, and K Saito, and A Hirata, and K Iwatsubo, and Y Noguchi, and H Yoshida
May 1982, Journal of neurochemistry,
N Fujita, and K Saito, and A Hirata, and K Iwatsubo, and Y Noguchi, and H Yoshida
October 1987, Journal of neurochemistry,
N Fujita, and K Saito, and A Hirata, and K Iwatsubo, and Y Noguchi, and H Yoshida
December 1982, European journal of pharmacology,
Copied contents to your clipboard!